Insulet (FRA:GOV) Total Liabilities : €1,687 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Insulet Total Liabilities?

Insulet's Total Liabilities for the quarter that ended in Mar. 2024 was €1,687 Mil.

Insulet's quarterly Total Liabilities declined from Sep. 2023 (€1,743.01 Mil) to Dec. 2023 (€1,701.49 Mil) and declined from Dec. 2023 (€1,701.49 Mil) to Mar. 2024 (€1,686.64 Mil).

Insulet's annual Total Liabilities increased from Dec. 2021 (€1,320.86 Mil) to Dec. 2022 (€1,675.32 Mil) and increased from Dec. 2022 (€1,675.32 Mil) to Dec. 2023 (€1,701.49 Mil).

Insulet Total Liabilities Historical Data

The historical data trend for Insulet's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Total Liabilities Chart

Insulet Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

960.30

1,043.37

1,320.86

1,675.32

1,701.49

Insulet Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,668.40	1,690.84	1,743.01	1,701.49	1,686.64

Insulet Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Insulet's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	413.75	+	(1252.989	+	34.754
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,701

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2373.379	-	671.886
	=	1,701

Insulet's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	397.808	+	(1253.592	+	35.236
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	1,687

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	2414.08	-	727.444
	=	1,687

Insulet Total Liabilities Related Terms

Thank you for viewing the detailed overview of Insulet's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Insulet (FRA:GOV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (FRA:GOV) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

PODD:USA PODD:Mexico

Address

100 Nagog Park, Acton, MA, USA, 01720

Website

https://www.insulet.com

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.

Insulet (FRA:GOV) Headlines

No Headlines